(Mn-DPDP) This agent, mangafodipir trisodium, is a hepatocyte specific MRI contrast agent. Manganese is very toxic, so it has to be chelated and put in the form of a vitamin B6 analog, which is taken up by normal hepatocytes to some extent.
Teslascan® was developed in the early 1980's, went through clinical trials in the early 1990's, and was approved in 1997. One problem with assessing the efficacy of this agent is the fact that the phase III trials finished in the early 1990's, and the techniques used for MR today are very different from the techniques used almost a decade ago.
This contrast agent shortens the T1 relaxation time. On T1 weighted pictures it makes a normal liver look brighter. Since metastases, for example, do not generally take up this agent, the contrast between the enhancing liver and the non-enhancing lesions will increase on T1 weighted pictures. It does not have much effect on T2 weighted images.

(TFE) Turbo field echo is a gradient echo pulse sequence with data acquisition after an initial 180° (similar to IR) preparation pulse for contrast enhancement. The difference between a FFE and TFE other than the speed of the sequence is that the image is acquired while approaching steady state (the echoes are collected during the time in which the tissues are experiencing T1 relaxation).
The contrast is prepared one time, which means the contrast is changing while the echoes are collected and can be manipulated by selecting the type and timing of the prepulse. A delay time is given before the actual image acquisition. To achieve T1 contrast the 180° prepulse is followed by an operator selected delay time, that results in no signal from the targeted tissue. So when the echoes are acquired, no signal is present, additional RF spoiling is performed to optimize for T1 contrast. The delay chosen corresponds to when T1 relaxation reaches and suppresses T1 signal or optimizes the difference between tissues. Contrast for these sequences are enhanced when K-space is filled using a centric or low-high ordering. A TFE can be acquired with a 2D or 3D technique and with or without T1, T2 weighting.
See Ultrafast Gradient Echo Sequence, TurboFLASH and Magnetization Prepared Rapid Gradient Echo (MPRAGE).

An ultrafast gradient echo pulse sequence with data acquisition after an initial 180° (similar to IR) preparation pulse for contrast enhancement.
See Fast Low Angle Shot and Ultrafast Gradient Echo Sequence.

Vasovistâ„¢ is an albumin-targeted intravascular contrast agent. It is indicated for contrast enhanced MR angiography (CE-MRA) for the visualization of abdominal or limb vessels in patients with suspected or known vascular disease. After IV injection, Vasovistâ„¢ binds reversibly to human albumin in plasma, which results in long-lasting increased relaxivity. Imaging from 5 to 50 min is possible. A small unbound portion is, by glomerular filtration, eliminated by the kidneys.
AngioMARK® was the formerly trade name and MS-325 the research name. Currently the phase III clinical trials are completed to determine its efficacy for peripheral vascular disease and coronary artery disease.
In the U.S., EPIX received an approvable letter from the U.S. Food and Drug Administration (FDA) for Vasovistâ„¢ in January 2005. In 2009, Epix Pharmaceuticals has sold the U.S., Canadian and Australian rights for its blood pool agent (now named ABLAVARâ„¢), to Lantheus Medical Imaging, Inc..

WARNING: NEPHROGENIC SYSTEMIC FIBROSIS Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m²), or acute renal insufficiency of any severity due to the hepato-renal syndrome or the liver transplantation period.

See also MRI Safety.

Inert hyperpolarized gases are under development for imaging air spaces, including those in the lungs. Because they mostly contain air and water, lungs are difficult organs to image.
These ventilation agents (gases) have potential in lung imaging and are currently used in studies of the pulmonary ventilation:
Specific isotopes of inert gases can be hyperpolarized. Hyperpolarized is a state in which almost all of the atoms nuclei are spinning in the same direction. Once the nuclei in the isotope 3He have been hyperpolarized using a laser, they remain in this state for several days. The inert, hyperpolarized gas can then be used in a lung imaging study, where the high concentration of polarized nuclei provides a sharp contrast in MRI. The technique is already being developed with a view to commercialization by Magnetic Imaging Technologies in Durham, North Carolina. According to the company, existing MRI equipment can be used with a few minor modifications, along with a gas polarizer. The technique could provide early detection and monitoring of pulmonary disease.
Hyperpolarized 129Xe can also be used as a magnetic resonance tracer because of its MR-enhanced sensitivity combined with its high solubility. This isotope differs from 3He in that it can dissolve in the blood. Strong enhancement of the nuclear spin polarization of xenon in the gas phase can be achieved by optical pumping of rubidium and subsequent spin-exchange with the xenon nuclei. This technique can increase the magnetic resonance signal of xenon by five orders of magnitude, thus allowing NMR detection of xenon in very low concentration. MR spectroscopy and imaging of optically polarized xenon shows considerable potential for medical applications (see also back projection imaging).
Nycomed Amersham anticipated the market for inert gases in pulmonary imaging. The company obtained an exclusive license for the use of helium (He) and xenon (Xe) as MRI contrast agents. Currently, the US FDA has not yet approved the commercial distribution of inert gas imaging equipment, because the technique is still undergoing trials.